Results 171 to 180 of about 20,603 (248)

Advancing Treatment of Degenerative Eye Diseases at the Nanoscale

open access: yesSmart Medicine, Volume 5, Issue 4, August 2026.
Nanotherapeutics possess the potential to overcome longstanding bottlenecks in treating degenerative ophthalmic diseases. With a highly tunable surface chemistry, nanotechnology platforms can be customized to navigate specific anatomical barriers in the eye and target pathways of diseases.
Li Yao Jin   +5 more
wiley   +1 more source

Microenvironment‐Responsive Drug Delivery Systems for Ocular Surface Diseases: Mechanisms, Applications, and Translational Challenges

open access: yesSmall Science, Volume 6, Issue 8, August 2026.
Microenvironment‐responsive drug delivery systems overcome ocular physiological barriers by responding to temperature, pH, ions, reactive oxygen species, and enzymes. This review bridges material design, performance evaluation, and clinical translation, offering actionable insights for treating dry eye disease, infectious keratitis, and corneal ...
Jiamin Liu   +3 more
wiley   +1 more source

Astigmatic changes after Descemet membrane endothelial keratoplasty (DMEK) in decompensated penetrating keratoplasty grafts

open access: yesActa Ophthalmologica, Volume 104, Issue 5, Page e516-e529, August 2026.
Abstract Purpose To evaluate the surgery‐induced changes of astigmatism after Descemet membrane endothelial keratoplasty (DMEK) in eyes with failed previous penetrating keratoplasty (PK). Design Retrospective, interventional cohort study based on prospective DMEK database.
Florian Thomas Steinberg   +6 more
wiley   +1 more source

Probable sepsis‐associated encephalopathy as a component of multiple organ dysfunction syndrome in a cat with pyothorax

open access: yesAustralian Veterinary Journal, Volume 104, Issue 8, Page 523-531, August 2026.
A 2‐year‐old male neutered domestic shorthair cat with bacterial pyothorax was referred to a tertiary hospital for treatment of sepsis. He met criteria for multiple organ dysfunction syndrome and developed new‐onset neurological dysfunction subsequent to the development of sepsis.
CC Chan, CR Sharp, CJ Boyd
wiley   +1 more source

Neurokinin‐1 receptor activation protects against cardiac fibrosis, inflammation and diastolic dysfunction in type 2 diabetic mice

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 15, Page 4246-4266, August 2026.
Background and Purpose The pathogenesis of type 2 diabetes mellitus (T2DM)‐induced cardiomyopathy involves cardiac fibrosis that leads to diastolic dysfunction. We established that replacement of lost substance P (SP) that occurs in T2DM reduces cardiac fibrosis and decreases inflammation in T2DM mice and non‐human primates.
Alexander Widiapradja   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy